The present invention is directed to dihydrochloric acid and dibenzenesulfonicacid salts of the c-Met kinase inhibitor2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositionsthereof, useful in the treatment of cancer and other diseases related to thedysregulation of kinase pathways. The presentinvention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.